Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis

Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis

Objectives Pharmaceutical innovation can contribute to reducing the burden of disease in human populations. This research asks whether products approved by the US Food and Drug Administration (FDA) from 2010 to 2019 and expedited review programmes incentivising development of products for serious di...

Full description

Bibliographic Details
Main Authors:	Matthew J Jackson, Gregory Vaughan, Fred D Ledley
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/14/3/e076542.full

Similar Items

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
by: Bao Liu, et al.
Published: (2022-07-01)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
by: Fei Liang, et al.
Published: (2020-08-01)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
by: Nadia Zuabi, et al.
Published: (2016-11-01)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
by: Jingjing Yu, et al.
Published: (2020-07-01)

Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023
by: Dana E. Moseson, et al.
Published: (2024-06-01)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
by: Joshua D. Wallach, et al.
Published: (2019-06-01)

Endovascular Strategies for Aortic Arch When US Food and Drug Administration–Approved Devices Are Not Available
by: Gabrielle Sutton, MS, et al.
Published: (2024-03-01)

Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration Animal rule
by: Chia-Wei eTsai, et al.
Published: (2015-12-01)

Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
by: Enrique Seoane-Vazquez, et al.
Published: (2024-02-01)

Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration
by: Michelle B. Nadler, et al.
Published: (2024-01-01)

Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations
by: Yassine Kamal Lyauk, et al.
Published: (2019-09-01)

A U.S. Food and Drug Administration perspective on cannabis research and drug development
by: Cassandra L. Taylor, et al.
Published: (2023-10-01)

US food and drug administration Indian site inspections: An experience
by: Pooja Mahajan, et al.
Published: (2012-01-01)

Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals
by: Bhaven C. Kataria, et al.
Published: (2013-01-01)

A protocol for topographic-guided corneal repair utilizing the US Food and Drug Administration-approved Wavelight Contoura
by: Motwani M
Published: (2017-03-01)

The United States Food and Drug Administration’s Platform Technology Designation to Expedite the Development of Drugs
by: Sarfaraz K. Niazi
Published: (2024-07-01)

Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs
by: Muhammad Shahzeb Khan, et al.
Published: (2020-06-01)

Severe malaria, pascalian therapeutics, and the US Food and Drug Administration (FDA)
by: White, NJ, et al.
Published: (2022)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
by: Joe Lex
Published: (2016-11-01)

The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration
by: Zineh Issam, et al.
Published: (2010-04-01)

Vaccines, Pharmaceutical Products, and Bioterrorism: Challenges for the U.S. Food and Drug Administration
by: Kathryn C. Zoon
Published: (1999-08-01)

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration.
by: Helen W Sullivan, et al.
Published: (2016-01-01)

The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases.
by: Michael J Brennan
Published: (2009-07-01)

Differentiation therapy of the neoplastic stromal cells in giant cell tumor of bone using the U.S. Food and Drug Administration (FDA)-approved drugs, rapamycin and simvastatin
by: Carol P.Y. Lau, et al.
Published: (2016-10-01)

Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
by: Alexander C. Martins, et al.
Published: (2024-09-01)

Innovation Process and Industrial System of US Food and Drug Administration–Approved Software as a Medical Device: Review and Content Analysis
by: Jiakan Yu, et al.
Published: (2023-11-01)

Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products.
by: Stanton A Glantz, et al.
Published: (2009-07-01)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
by: Carrie M. Kuehn
Published: (2019-08-01)

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration.
by: Robert K M Choy, et al.
Published: (2020-07-01)

Potential consumer response to the healthy symbol proposed by the U.S. food and Drug Administration
by: Jillian Hyink, et al.
Published: (2024-05-01)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
by: Gelareh A. Abulwerdi, et al.
Published: (2023-10-01)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023-04-01)

A review of new drugs approved by the food and drug administration in 2022
by: Arjun Swaminathan, et al.
Published: (2023-10-01)

Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
by: Roman Adam, et al.
Published: (2022-01-01)

Clinical benefit of cancer drugs approved in Switzerland 2010–2019
by: Roman Adam, et al.
Published: (2022-01-01)

Increased Confidence in Deduplication of Drug Safety Reports with Natural Language Processing of Narratives at the US Food and Drug Administration
by: Kory Kreimeyer, et al.
Published: (2022-06-01)

Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration
by: Jane E B Reusch, et al.
Published: (2024-12-01)

Adverse Events Involving Hallux Metatarsophalangeal Joint Implants: Comprehensive Analysis of US Food and Drug Administration Data from 2010 to 2018
by: Craig C. Akoh MD, et al.
Published: (2020-10-01)

Handbook of U.S. colorants for foods, drugs, and cosmetics/
by: 225351 Marmion, Daniel M.
Published: (1984)